The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Official Title: A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients
Study ID: NCT03096093
Brief Summary: This study evaluates four different doses of ACIT-1 for safety and for the ability to raise effective anti-cancer immune responses in patients with pancreatic and other cancers. Approximately half of the patients will have pancreatic cancer and the other half will have other cancers.
Detailed Description: The immune system has an important role in helping prevent cancer by destroying early cancer cells. When cancer does develop antigen-specific immune (T) cells are still present in the blood but are either not responding or are not effective. Vaccines stimulate these T cells to respond and kill cancer cells. ACIT-1 is designed to stimulate tumour antigen-specific T cells to respond and kill cancer cells.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom
Name: Daniel H Palmer, MBChB PhD
Affiliation: Clatterbridge Cancer Centre
Role: PRINCIPAL_INVESTIGATOR